Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

Inclusion Criteria:

1. Male or female patients >= 18 years of age

2. ECOG Performance Status of 0, 1, or 2

3. Patient with diagnosis of BCR-ABL positive CML CP

4. Patient has received a minimum of 3 years of tyrosine kinase inhibitor treatment
(first with imatinib (> 4 weeks) and then switched to nilotinib) since initial
diagnosis

5. Patient has at least 2 years of nilotinib treatment prior to study entry.

6. Patient has achieved MR4.5 (local laboratory assessment) during nilotinib treatment,
and determined by a Novartis designated central PCR lab assessment at screening

7. Adequate end organ function as defined by:

- Direct bilirubin ≤ 1.5 x ULN except for i) patient with documented Gilbert's
syndrome for whom any bilirubin value is allowed and ii) for patients with
asymptomatic hyperbilirubinemia (liver transaminases and alkaline phosphatase
within normal range)

- SGOT(AST) and SGPT(ALT) < 3 x ULN (upper limit of normal)

- Serum lipase ≤ 2 x ULN

- Alkaline phosphatase ≤ 2.5 x ULN

- Serum creatinine < 1.5 x ULN

8. Patients must have the following electrolyte values ≥ LLN (lower limit of normal)
limits or corrected to within normal limits with supplements prior to the first dose
of study medication:

- Potassium

- Magnesium

- Total calcium (corrected for serum albumin)

9. Patients must have normal marrow function as defined below:

- Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L

- Platelets ≥ 100 x 109/L

- Hemoglobin ≥ 9.0 g/dL

10. Written informed consent obtained prior to any screening procedures

Exclusion Criteria:

1. Prior AP, BC or allo-transplant

2. Patient has documented MR4.5 at the time when switched from imatinib to nilotinib

3. Patients with known atypical transcript

4. CML treatment resistant mutation(s) (T315I, E255K/V, Y253H, F359C/V) detected if a
testing was done in the past (there is no requirement to perform mutation testing at
study entry if it was not done in the past)

5. Dose reductions due to neutropenia or thrombocytopenia in the past 6 months

6. Patient ever attempted to permanently discontinue imatinib or nilotinib treatment

7. Known impaired cardiac function including any one of the following:

- Inability to determine the QT interval on ECG

- Complete left bundle branch block

- Long QT syndrome or a known family history of long QT syndrome

- History of or presence of clinically significant ventricular or atrial
tachyarrhythmias

- Clinically significant resting bradycardia

- QTcF > 480 msec

- History or clinical signs of myocardial infarction within 1 year prior to study
entry

- History of unstable angina within 1 year prior to study entry

- Other clinically significant heart disease (e.g. uncontrolled congestive heart
failure or uncontrolled hypertension)

8. Severe and/or uncontrolled concurrent medical disease that in the opinion of the
investigator could cause unacceptable safety risks or compromise compliance with the
protocol (e.g. uncontrolled diabetes (defined as HbA1c > 9%), uncontrolled infection)

9. History of acute pancreatitis within 1 year prior to study entry or past medical
history of chronic pancreatitis

10. Known presence of a significant congenital or acquired bleeding disorder unrelated to
cancer

11. History of other active malignancy within 5 years prior to study entry with the
exception of previous or concomitant basal cell skin cancer, previous cervical
carcinoma in situ treated curatively

12. Patients who have not recovered from prior surgery

13. Treatment with other investigational agents (defined as not used in accordance with
the approved indication) within 4 weeks of Day 1

14. Patients actively receiving therapy with strong CYP3A4 inhibitors and/or inducers, and
the treatment cannot be either discontinued or switched to a different medication
prior to study entry. See Appendix 14.1 for a list of these medications. This list may
not be comprehensive.

15. Patients actively receiving therapy with herbal medicines that are strong CYP3A4
inhibitors and/or inducers, and the treatment cannot be either discontinued or
switched to a different medication prior to study entry. These herbal medicines may
include Echinacea, (including E. purpurea, E. angustifolia and E. pallida), Piperine,
Artemisinin, St. John's Wort, and Ginkgo.

16. Patients who are currently receiving treatment with any medications that have the
potential to prolong the QT interval and the treatment cannot be either safely
discontinued or switched to a different medication prior to study entry. (Please see
www.azcert.org/medical-pros/drug-lists/printable-drug-list.cfm for a list of agents
that prolong the QT interval.)

17. Impairment of gastrointestinal (GI) function or GI disease that may significantly
alter the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea,
vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass
surgery)

18. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
female after conception and until the termination of gestation, confirmed by a
positive hCG laboratory test.

19. Women of child-bearing potential, defined as all women physiologically capable of
becoming pregnant, must have a negative serum pregnancy test before initiation of
study treatment and must also use highly effective methods of contraception while
enrolled in the study. The use of highly effective contraception should continue for
at least 14 days after the last dose of study treatment or until the last day of
TFR/TFR-2, or for the duration of a monthly cycle of oral contraception, whichever is
longer. Acceptable forms of highly effective contraception methods include:

a. Total abstinence (when this is in line with the preferred and usual lifestyle of
the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal,
post-ovulation methods) and withdrawal are not acceptable methods of contraception and
male/female sterilization defined as:

- Female sterilization (have had surgical bilateral oophorectomy with or without
hysterectomy) or tubal ligation at least six weeks before taking study treatment.
In case of oophorectomy alone, only when the reproductive status of the woman has
been confirmed and documented by follow up hormone level assessment

- Male sterilization (at least 6 months prior to screening). For female patients on
the study, study participation assumes the vasectomized male partner is the sole
partner for that patient or b. A combination of any two of the following (i+ii or
i+iii or ii+iii): i) Barrier methods of contraception: condom or occlusive cap
(diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal
suppository ii) Use of oral, injected or implanted hormonal methods of
contraception or other forms of hormonal contraception that have comparable
efficacy (failure rate <1%), for example hormone vaginal ring or transdermal
hormone contraception iii) Placement of an intrauterine device (IUD) or
intrauterine system (IUS)